Ranjita Das

Title: Ranjita Das - Innovator in Cancer Treatment

Introduction

Ranjita Das is a notable inventor based in Kolkata, India. He has made significant contributions to the field of cancer treatment through his innovative research and development. His work focuses on the isolation of organic compounds that have therapeutic potential against various types of cancer.

Latest Patents

Ranjita Das holds a patent for a process that isolates organic compounds useful for the treatment of cancer. The patent specifically addresses two main components, mahanine and mahanimbine (dehydroxy-mahanine), which are effective against glioblastoma and cervical carcinoma. Mahanimbine has demonstrated anti-cancer activity against multiple cancer types, including lymphoid leukemia, myeloid leukemia, glioma, cervical carcinoma, pancreatic, colon, and lung cancers. The cytotoxicity of these compounds is attributed to the C-3 hydroxy and NH groups. Notably, mahanine has been shown to reduce the doses of cisplatin and paclitaxel in cervical cancer, enhancing efficacy while minimizing toxicity. A new, cost-effective process for the preparation of these compounds has also been established, with the EtOAc extract containing alkaloids enriched with mahanimbine and mahanine proving active against glioma and cervical cancers.

Career Highlights

Ranjita Das is affiliated with the Council of Scientific and Industrial Research, where he continues to advance his research in cancer treatment. His innovative approaches and dedication to scientific inquiry have positioned him as a key figure in the field.

Collaborations

Ranjita has collaborated with notable colleagues, including Chitra Mandal and Bikas Chandra Pal, who have contributed to his research endeavors.

Conclusion

Ranjita Das's work in isolating organic compounds for cancer treatment exemplifies the impact of innovation in medical research. His contributions are paving the way for more effective therapies against challenging cancer types.